Based on the NEO3-06 study results and data analysis, we are working to file an sNDA for Lymphoseek by year end."
If they already had a meeting with the FDA, the agency already knows about the snda this should be approved for the expanded label. Why wouldn't the chance of selling Lymphoseek procedures to other cancer cases raise the stock price?????? I dont get it.??????? The stock price should reflect future value no????